PEPDar: a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis
Objectives PEPDar compared the tolerability and safety of ritonavir-boosted darunavir (DRV/r)-based post-exposure prophylaxis (PEP) with the tolerability and safety of standard of care (SOC). The primary endpoint was the early discontinuation rate among the per-protocol population. Methods PEPDar wa...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2016 May 11
|
| In: |
HIV medicine
Year: 2016, Jahrgang: 17, Heft: 6, Pages: 453-459 |
| ISSN: | 1468-1293 |
| DOI: | 10.1111/hiv.12363 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1111/hiv.12363 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/hiv.12363 
|
| Verfasserangaben: | G. Fätkenheuer, H. Jessen, A. Stoehr, N. Jung, A.B. Jessen, T. Kümmerle, M. Berger, J.R. Bogner, C. D. Spinner, C. Stephan, O. Degen, R. Vogelmann, P. Spornraft‐Ragaller, E. Schnaitmann, B. Jensen, A. Ulmer, J.M. Kittner, G. Härter, P. Malfertheiner, J. Rockstroh, G. Knecht, S. Scholten, T. Harrer, W.V. Kern, B. Salzberger, D. Schürmann and B. Ranneberg |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 158848663X | ||
| 003 | DE-627 | ||
| 005 | 20220815121000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190308s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hiv.12363 |2 doi | |
| 035 | |a (DE-627)158848663X | ||
| 035 | |a (DE-576)51848663X | ||
| 035 | |a (DE-599)BSZ51848663X | ||
| 035 | |a (OCoLC)1341041156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fätkenheuer, Gerd |e VerfasserIn |0 (DE-588)1036523861 |0 (DE-627)751086487 |0 (DE-576)160901154 |4 aut | |
| 245 | 1 | 0 | |a PEPDar |b a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis |c G. Fätkenheuer, H. Jessen, A. Stoehr, N. Jung, A.B. Jessen, T. Kümmerle, M. Berger, J.R. Bogner, C. D. Spinner, C. Stephan, O. Degen, R. Vogelmann, P. Spornraft‐Ragaller, E. Schnaitmann, B. Jensen, A. Ulmer, J.M. Kittner, G. Härter, P. Malfertheiner, J. Rockstroh, G. Knecht, S. Scholten, T. Harrer, W.V. Kern, B. Salzberger, D. Schürmann and B. Ranneberg |
| 264 | 1 | |c 2016 May 11 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.03.2019 | ||
| 520 | |a Objectives PEPDar compared the tolerability and safety of ritonavir-boosted darunavir (DRV/r)-based post-exposure prophylaxis (PEP) with the tolerability and safety of standard of care (SOC). The primary endpoint was the early discontinuation rate among the per-protocol population. Methods PEPDar was an open-label, randomized, multicentre, prospective, noninferiority safety study. Subjects were stratified by type of event (occupational vs. nonoccupational, i.e. sexual) and were randomized to receive DRV/r plus two nucleoside reverse transcriptase inhibitors (NRTIs) or SOC PEP. Twenty-two private or university HIV clinics in Germany participated. Subjects were ≥ 18 years old and had documented or potential HIV exposure and indication for HIV PEP. They initiated PEP not later than 72 h after the event and were HIV negative. Results A total of 324 subjects were screened, the per-protocol population was 305, and 273 subjects completed the study. One hundred and fifty-five subjects received DRV/r-based PEP and 150 subjects received ritonavir-boosted lopinavir (LPV/r)-based PEP for 28-30 days; 298 subjects also received tenofovir/emtricitabine. The early discontinuation rate in the DRV/r arm was 6.5% compared with 10.0% in the SOC arm (P = 0.243). Adverse drug reactions (ADRs) were reported in 68% of DRV/r subjects and 75% of SOC subjects (P = 0.169). Fewer DRV/r subjects (16.1%) had at least one grade 2 or 3 ADR compared with SOC subjects (29.3%) (P = 0.006). All grades of diarrhoea, nausea, and sleep disorders were significantly less frequent with DRV/r, while headache was significantly more frequent. No HIV seroconversion was reported during follow-up. Conclusions Noninferiority of DRV/r to SOC was demonstrated. DRV/r should be included as a standard component of recommended regimens in PEP guidelines. | ||
| 650 | 4 | |a darunavir | |
| 650 | 4 | |a lopinavir | |
| 650 | 4 | |a occupational exposure | |
| 650 | 4 | |a post-exposure prophylaxis | |
| 650 | 4 | |a sexual exposure | |
| 700 | 1 | |a Vogelmann, Roger |d 1969- |e VerfasserIn |0 (DE-588)123267099 |0 (DE-627)706233980 |0 (DE-576)293629579 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV medicine |d Oxford [u.a.] : Wiley-Blackwell, 1999 |g 17(2016), 6, Seite 453-459 |h Online-Ressource |w (DE-627)320602478 |w (DE-600)2020341-X |w (DE-576)091143667 |x 1468-1293 |7 nnas |a PEPDar a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis |
| 773 | 1 | 8 | |g volume:17 |g year:2016 |g number:6 |g pages:453-459 |g extent:7 |a PEPDar a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.12363 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/hiv.12363 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190308 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 123267099 |a Vogelmann, Roger |m 123267099:Vogelmann, Roger |d 60000 |d 61100 |e 60000PV123267099 |e 61100PV123267099 |k 0/60000/ |k 1/60000/61100/ |p 12 | ||
| 999 | |a KXP-PPN158848663X |e 305786290X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"PEPDar","title":"PEPDar","subtitle":"a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Fätkenheuer, Gerd","given":"Gerd","family":"Fätkenheuer"},{"given":"Roger","family":"Vogelmann","role":"aut","display":"Vogelmann, Roger","roleDisplay":"VerfasserIn"}],"note":["Gesehen am 08.03.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"158848663X","language":["eng"],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"2016 May 11"}],"id":{"eki":["158848663X"],"doi":["10.1111/hiv.12363"]},"name":{"displayForm":["G. Fätkenheuer, H. Jessen, A. Stoehr, N. Jung, A.B. Jessen, T. Kümmerle, M. Berger, J.R. Bogner, C. D. Spinner, C. Stephan, O. Degen, R. Vogelmann, P. Spornraft‐Ragaller, E. Schnaitmann, B. Jensen, A. Ulmer, J.M. Kittner, G. Härter, P. Malfertheiner, J. Rockstroh, G. Knecht, S. Scholten, T. Harrer, W.V. Kern, B. Salzberger, D. Schürmann and B. Ranneberg"]},"physDesc":[{"extent":"7 S."}],"relHost":[{"part":{"pages":"453-459","issue":"6","year":"2016","extent":"7","volume":"17","text":"17(2016), 6, Seite 453-459"},"pubHistory":["1.1999/2000 -"],"language":["eng"],"recId":"320602478","disp":"PEPDar a randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxisHIV medicine","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 28.03.2022"],"title":[{"title":"HIV medicine","title_sort":"HIV medicine"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["320602478"],"doi":["10.1111/(ISSN)1468-1293"],"zdb":["2020341-X"],"issn":["1468-1293"]},"origin":[{"dateIssuedKey":"1999","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedDisp":"1999-","publisherPlace":"Oxford [u.a.] ; Oxford [u.a.] ; Oxford [u.a.]"}]}]} | ||
| SRT | |a FAETKENHEUPEPDAR2016 | ||